For personal use only

Quarterly Activities Report

31 October 2020: Personalized Oncology life sciences company **Invitrocue Limited (ASX: IVQ), ('Invitrocue', 'the Company' or 'the Group'),** is pleased to provide this quarterly activities report to its appendix 4C reporting for the quarter ended 30 September 2020 (Q1 FY2021).

Operational cashflow

With the easing of COVID-19 cases in Singapore, the Group's operations improved, with receipts of S$391,000 collected, an increase of 155% compared to previous quarter's receipt of S$155,000.

In addition, the Company has received new orders totaling about S$495,000 during this period, a sign of the continuing demand for health science related services even in the midst of the COVID-19 pandemic.

During this quarter, the Group received about S$67,000 of government's employment support.

Europe operations

The completion of CE Mark registration on our Onco-PDO® cancer test in Europe has pave the way for the test to be commercially available to oncologists and patients across Europe, while at the same time seeking to list our Onco-PDO® test under the German Healthcare reimbursement system.

However, this has been slowed by the 2nd COVID-19 wave in Europe. The Company is currently working closely with our Europe colleagues and partners to prepare as much as possible so that the Europe roll-out can be fast tracked once the COVID-19 situation eases in Europe.

Financial reports

The Company is working with its auditors on resolving the issues raised by auditors with regards to it 31 December 2019 half year report and 30 June 2020 annual report.

Payments to related parties of the entity and their associates

A total of S$112,000 has been paid to directors, of which S$85,000 is for payment of directors' remuneration, while S$27,000 is for payment of corporate services rendered by

End

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

For personal use only

Name of entity	
Invitrocue Limited	
ABN	**Quarter ended ("current quarter")**
50 009 366 009	30 September 2020

Consolidated statement of cash flows		**Current quarter $A'000**	**Year to date (...3....months) $A'000**
1.	**Cash flows from operating activities**		
1.1	Receipts from customers	391	391
1.2	Payments for		
	(a) research and development	-	-
	(b) product manufacturing and operating costs	(208)	(208)
	(c) advertising and marketing	-	-
	(d) leased assets	(85)	(85)
	(e) staff costs	(752)	(752)
	(f) administration and corporate costs	(307)	(307)
1.3	Dividends received (see note 3)	-	-
1.4	Interest received	-	-
1.5	Interest and other costs of finance paid	(13)	(13)
1.6	Income taxes paid	-	-
1.7	Government grants and tax incentives	67	67
1.8	Other (provide details if material)	-	-
1.9	**Net cash from / (used in) operating activities**	**(907)**	**(907)**

2.	**Cash flows from investing activities**		
2.1	Payments to acquire or for:		
	(a) entities		
	(b) businesses		
	(c) property, plant and equipment	(1)	(1)
	(d) investments		
	(e) intellectual property		
	(f) other non-current assets		

For personal use only

Consolidated statement of cash flows		Current quarter $A'000	Year to date (...3....months) $A'000
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
2.6	**Net cash from / (used in) investing activities**	**(1)**	**(1)**

3.	**Cash flows from financing activities**		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	-	-
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	-	-
3.4	Transaction costs related to issues of equity securities or convertible debt securities	-	-
3.5	Proceeds from borrowings	1,451	1,451
3.6	Repayment of borrowings	(10)	(10)
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (provide details if material)	-	-
3.10	**Net cash from / (used in) financing activities**	**1,441**	**1,441**

4.	**Net increase / (decrease) in cash and cash equivalents for the period**		
4.1	Cash and cash equivalents at beginning of period	641	641
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(907)	(907)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(1)	(1)

Consolidated statement of cash flows		Current quarter $A'000	Year to date (...3....months) $A'000
4.4	Net cash from / (used in) financing activities (item 3.10 above)	1,441	1,441
4.5	Effect of movement in exchange rates on cash held	8	8
4.6	**Cash and cash equivalents at end of period**	**1,182**	**1,182**

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter $A'000	Previous quarter $A'000
5.1	Bank balances	1,182	641
5.2	Call deposits	-	-
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	**Cash and cash equivalents at end of quarter (should equal item 4.6 above)**	**1,182**	**641**

6.	Payments to related parties of the entity and their associates	Current quarter $A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	112
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-

Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.

For personal use only

7.	**Financing facilities** *Note: the term "facility' includes all forms of financing arrangements available to the entity.* *Add notes as necessary for an understanding of the sources of finance available to the entity.*	**Total facility amount at quarter end $A'000**	**Amount drawn at quarter end $A'000**
7.1	Loan facilities	-	-
7.2	Credit standby arrangements	-	-
7.3	Other (please specify)	-	-
7.4	**Total financing facilities**	-	-

7.5	**Unused financing facilities available at quarter end**	
7.6	Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.	

8.	**Estimated cash available for future operating activities**	**$A'000**
8.1	Net cash from / (used in) operating activities (item 1.9)	(959)
8.2	Cash and cash equivalents at quarter end (item 4.6)	1,182
8.3	Unused finance facilities available at quarter end (item 7.5)	-
8.4	Total available funding (item 8.2 + item 8.3)	1,182
8.5	**Estimated quarters of funding available (item 8.4 divided by item 8.1)**	(1.3)

Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.

8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions:

8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?

Answer: Yes

8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?

Answer: Yes, the entity is in discussion with several sophisticated investors to raise further cash to fund its operations. The entity is confident the fund raisings will be successful.

8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?

Answer: Yes. The entity has successfully raised fund in the past, and believes it will continue to be able to do so in future to meet its business objectives.

Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.

For personal use only

Compliance statement

1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.

2 This statement gives a true and fair view of the matters disclosed.

Date: .....31 October 2020.....

Authorised by: .....Board of Directors.....
(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.

2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.

3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.

4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [*name of board committee – eg Audit and Risk Committee*]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".

5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.

For personal use only